MedTrace Logo

Role of Nerve Block in Management of Multiple Rib Fractures

NCT06958549 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-05-06

No results posted yet for this study

Summary

* Epidemiology \& Impact Thoracic trauma is a common and serious injury worldwide-especially in developing countries-and carries high rates of morbidity and mortality. Complications arise primarily from hypoventilation, which leads to atelectasis, pneumonia, and respiratory failure.
* Key to Reducing Complications: Pain Control Effective analgesia is the cornerstone of preventing respiratory complications. Inadequate pain relief causes patients to splint and hypoventilate, setting the stage for pulmonary collapse and infection.
* Conservative Management
* Analgesics: Systemic pharmacological pain relief remains the mainstay.
* Supportive Measures: Rest, application of ice, and encouragement of deep breathing exercises.
* Incentive Spirometry: Promoted in all patients to maintain lung expansion and ward off atelectasis.
* Regional Anesthesia Techniques

To further improve comfort and respiratory mechanics, ultrasound-guided nerve blocks are employed according to fracture location:

* Serratus Anterior Plane Block for anterolateral rib fractures
* Thoracic Paravertebral Block for posterior rib fractures
* Surgical Intervention Reserved for complex cases-such as flail chest or fractures with risk of organ injury-where stabilization or repair may be necessary.
* Identified Gap Despite these options, thoracic surgeons currently lack a standardized, procedure-specific pain management protocol beyond systemic analgesics, highlighting a need for consensus guidelines that integrate pharmacological and regional techniques.

Conditions

  • Multiple Rib Fractures

Interventions

PROCEDURE

Nerve block with Lidocain

Injection of Lidocaine (7mg/kg) with Epinephrine 1:100000 under Ultrasonographical guidance

DRUG

pharmacological analgesics

Oral Paracetamol (500mg/6hr), IV Ketolac (15mg/6hr) and IV perfelgan (1gm/6hr)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-12-31
Completion
2027-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06958549 on ClinicalTrials.gov